Justin

In this video, Justin, who lives with congenital hemophilia with inhibitors, talks about his love of travel and how NovoSeven® RT fits in when he’s living life on the go. When he’s traveling internationally, the compact packaging of NovoSeven® RT allows him to take it along.

Justin

In this video, Justin, who lives with congenital hemophilia with inhibitors, talks about his love of travel and how NovoSeven® RT fits in when he’s living life on the go. When he’s traveling internationally, the compact packaging of NovoSeven® RT allows him to take it along.

Chase

Chase was diagnosed with hemophilia as an infant. In this video, Chase and his grandmother discuss his favorite activities and how the quick infusion time and portability of NovoSeven® RT fit into their lives.

Chase

Chase was diagnosed with hemophilia as an infant. In this video, Chase and his grandmother discuss his favorite activities and how the quick infusion time and portability of NovoSeven® RT fit into their lives.

Recombinant manufacturing

minimizes risk of viral contamination.

New to treatment? It’s

easy to get started.

Considering

NovoSeven® RT?

Selected Important Safety Information

WARNING: BLOOD CLOTS

Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.

Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.

Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.

Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.

People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

The most common and serious side effects are blood clots.

Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).